Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cardiovascular Disease Events
100%
Trial Method
100%
Trial Design
100%
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
100%
Type 2 Diabetes Mellitus (T2DM)
50%
Cardiovascular Disease
50%
Type 2 Diabetic Patients
50%
Therapeutic Strategies
50%
Placebo
33%
Cardiovascular Risk
33%
Middle-aged
33%
Systolic Blood Pressure
33%
Cardiovascular Mortality
33%
Statins
33%
Glycemia
33%
HbA1c Levels
33%
Good Glycemic Control
33%
Lipids
16%
Treatment Strategy
16%
Obesity
16%
Health Problems
16%
Quality of Life
16%
Medical Treatment
16%
Risk Factors
16%
Public Health Risk
16%
High Risk
16%
Blood Pressure
16%
First Occurrence
16%
Health Care Costs
16%
Patients with Diabetes
16%
Disease-associated
16%
High-density Lipoprotein Cholesterol (HDL-C)
16%
Design Study
16%
Hemoglobin A1c (HbA1c)
16%
Low-density Lipoprotein Cholesterol (LDL-C)
16%
Clinical High Risk
16%
Triglyceride Level
16%
Blood Lipids
16%
Older Participants
16%
Non-fatal
16%
Event Rate
16%
Reductase Inhibitors
16%
Fenofibrate
16%
Primary Outcome Measure
16%
3-hydroxy-3-methylglutaryl-coenzyme A
16%
Cardiovascular Disease Morbidity
16%
Glycated Hemoglobin
16%
Nonfatal Myocardial Infarction
16%
Fibrates
16%
Incremental Risk
16%
Statin Drugs
16%
Risk for Cardiovascular Diseases
16%
Fibrate Drugs
16%
Nonfatal Stroke
16%
Biochemistry, Genetics and Molecular Biology
Statin
100%
Blood Pressure
66%
Systolic Blood Pressure
66%
Glucose Blood Level
66%
Glycemic Control
66%
Lipid
33%
Oxidoreductase
33%
Reductase
33%
HDL-Cholesterol
33%
Blood Lipids
33%
Triacylglycerol Level
33%
Fenofibrate
33%
HMG-CoA
33%
Glycated Hemoglobin
33%
Life Expectancy
33%
Low-Density Lipoprotein
33%
Medicine and Dentistry
Diabetes
100%
Cardiovascular Risk
100%
Cardiovascular Disease
100%
Maturity Onset Diabetes of the Young
27%
Patient with Type 2 Diabetes
27%
Statin
27%
Placebo
18%
Blood Pressure
18%
Systolic Blood Pressure
18%
Hemoglobin A1c
18%
Glycemic Control
18%
Health Care Cost
9%
Combination Therapy
9%
Cardiovascular System
9%
Quality of Life
9%
Public Health
9%
Myocardial Infarction
9%
Triacylglycerol
9%
Middle Age
9%
Cardiovascular Disease Risk Factor
9%
Life Expectancy
9%
High Density Lipoprotein Cholesterol
9%
Low Density Lipoprotein Cholesterol
9%
Patient with Diabetes
9%
Apoplexy
9%
Pressure Control
9%
Oxidoreductase
9%
Glycated Hemoglobin
9%
Diseases
9%
HMG-CoA
9%
Nursing and Health Professions
Cardiovascular Risk
100%
Cardiovascular Disease
100%
Non Insulin Dependent Diabetes Mellitus
25%
Patient with Type 2 Diabetes
25%
Placebo
16%
Blood Pressure
16%
Systolic Blood Pressure
16%
Hemoglobin A1c
16%
Glucose Blood Level
16%
Statin (Protein)
16%
Combination Therapy
8%
Heart Infarction
8%
Health Care Cost
8%
Quality of Life
8%
Life Expectancy
8%
Patient with Diabetes
8%
Low Density Lipoprotein Cholesterol
8%
Factorial Design
8%
High Density Lipoprotein Cholesterol
8%
Pressure Control
8%
Lipid Blood Level
8%
Cerebrovascular Accident
8%
Triacylglycerol Level
8%
Glycosylated Hemoglobin
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Nutrition Policy
8%
Diseases
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
Cardiovascular Disease
100%
Non Insulin Dependent Diabetes Mellitus
41%
Placebo
16%
Hemoglobin A1c
16%
Statin (Protein)
16%
Fibric Acid Derivative
16%
Oxidoreductase
8%
Combination Therapy
8%
Heart Infarction
8%
Triacylglycerol
8%
High Density Lipoprotein Cholesterol
8%
Low Density Lipoprotein Cholesterol
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Fenofibrate
8%
HMG-CoA
8%
Cerebrovascular Accident
8%
Glycosylated Hemoglobin
8%
Life Expectancy
8%
Diseases
8%